Sectoral Asset Management Inc. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 92.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,955 shares of the company’s stock after selling 167,240 shares during the quarter. Sectoral […]
Sectoral Asset Management Inc. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 92.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,955 shares of the company’s stock after selling 167,240 shares during the quarter. Sectoral […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $43.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 53.52% from the company’s […]
Cantor Fitzgerald restated their overweight rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $70.00 price target on the stock. Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) and Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends. Valuation and Earnings This table compares BridgeBio […]